Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aimmune Therapeutics Inc (Aimmune), a subsidiary of Societe Des Produits Nestle SA, is a clinical-stage biopharmaceutical company. It develops proprietary product candidates for the treatment of peanut, gastrointestinal, and metabolic-related diseases. The company's product pipeline includes a gastrointestinal portfolio comprised of CDX-7108 for exocrine pancreatic insufficiency, SER-287 and SER-301 ulcerative colitis, and PheFlo (CDX-6114) for phenylketonuria. Aimmune also discovers, develops, and commercializes therapies related to food allergy. The company conducts research and development in collaboration with leading biotechnology companies. It operates in the US, Ireland, Germany and the UK. Aimmune is headquartered in New Jersey, the US.
Headquarters
United States of America
Address
Building JR2, Suite E102, 1007 US Highway 202/206, Bridgewater, New Jersey, 08807
Website
www.aimmune.com
Telephone
1 650 6145220
Industry
Pharmaceuticals and Healthcare
Aimmune Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| CDX-7108: Exocrine Pancreatic Insufficiency |
| PheFlo (CDX-6114)-Orally Administered ERT Phenylketonuria |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Aimmune Therapeutics Inc | Abgent (Inactive) | Eidos Therapeutics Inc | Immunomic Therapeutics Inc | Ridgeback Biotherapeutics LLC |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Bridgewater | San Diego | San Francisco | Rockville | Miami |
| State/Province | New Jersey | California | California | Maryland | Florida |
| No. of Employees | - | - | 45 | - | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer